Literature DB >> 15462107

Gabapentin versus levodopa for the treatment of Restless Legs Syndrome in hemodialysis patients: an open-label study.

Hasan Micozkadioglu1, Fatma Nurhan Ozdemir, Altug Kut, Siren Sezer, Umit Saatci, Mehmet Haberal.   

Abstract

BACKGROUND: Restless Legs Syndrome (RLS), a common problem increasing morbidity and mortality in hemodialysis (HD) patients, affects 20-30% of uremic patients. Our aim was to find the efficacy of gabapentin in the treatment of RLS in HD patients by comparing a largely used drug, levodopa.
METHODS: Patients with RLS answered three questionnaires (RLS rating scale proposed by IRLSSG, the Short Form (SF)-36 and the Pittsburgh Sleep Quality Index) for the evaluation of severity of RLS, effects on quality of life and quality of sleep.
RESULTS: Fifteen patients (4.7%) (5 F, 10 M) with a mean age of 45.8+/-15.3 years got RLS diagnosis. When we compare the two drugs for severity of RLS symptoms relief, the effect of gabapentin was more significant (p<0.001). Gabapentin significantly improved general health, body pain and social functions (p<0.001). Moreover, regarding sleep parameters, gabapentin was significantly superior to levodopa for sleep quality, sleep latency (p<0.001) and sleep disturbance (p<0.000).
CONCLUSION: To our knowledge this was the first study comparing gabapentin and levodopa efficacy for the treatment of RLS in HD patients. Our results suggested that gabapentin is an effective drug for the management of RLS in hemodialysis patients.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15462107     DOI: 10.1081/jdi-120039823

Source DB:  PubMed          Journal:  Ren Fail        ISSN: 0886-022X            Impact factor:   2.606


  34 in total

Review 1.  Management of restless legs syndrome in patients on dialysis.

Authors:  Miklos Z Molnar; Marta Novak; Istvan Mucsi
Journal:  Drugs       Date:  2006       Impact factor: 9.546

2.  Recent advances in the diagnosis, genetics and treatment of restless legs syndrome.

Authors:  Claudia Trenkwalder; Birgit Högl; Juliane Winkelmann
Journal:  J Neurol       Date:  2009-04-27       Impact factor: 4.849

3.  Restless legs syndrome: a unique case and essentials of diagnosis and treatment.

Authors:  Pinky Agarwal; Alida Griffith
Journal:  Medscape J Med       Date:  2008-12-31

Review 4.  [Neurophysiological and neuroimaging studies for restless legs syndrome and periodic leg movement disorder].

Authors:  S Happe; W Paulus
Journal:  Nervenarzt       Date:  2006-06       Impact factor: 1.214

Review 5.  The treatment of restless legs syndrome and periodic limb movement disorder in adults--an update for 2012: practice parameters with an evidence-based systematic review and meta-analyses: an American Academy of Sleep Medicine Clinical Practice Guideline.

Authors:  R Nisha Aurora; David A Kristo; Sabin R Bista; James A Rowley; Rochelle S Zak; Kenneth R Casey; Carin I Lamm; Sharon L Tracy; Richard S Rosenberg
Journal:  Sleep       Date:  2012-08-01       Impact factor: 5.849

6.  Restless legs syndrome in hemodialysis patients: association with depression and quality of life.

Authors:  Deniz Tuncel; Fatma Ozlem Orhan; Hayriye Sayarlioglu; Ismet Onder Isık; Uygar Utku; Aytac Dinc
Journal:  Sleep Breath       Date:  2010-07-01       Impact factor: 2.816

7.  A randomized, double-blind, placebo-controlled, crossover study of XP13512/GSK1838262 in the treatment of patients with primary restless legs syndrome.

Authors:  Clete A Kushida; Arthur S Walters; Philip Becker; Stephen G Thein; A Thomas Perkins; Thomas Roth; Daniel Canafax; Ronald W Barrett
Journal:  Sleep       Date:  2009-02       Impact factor: 5.849

Review 8.  Sleep Disorders, Restless Legs Syndrome, and Uremic Pruritus: Diagnosis and Treatment of Common Symptoms in Dialysis Patients.

Authors:  Jennifer S Scherer; Sara A Combs; Frank Brennan
Journal:  Am J Kidney Dis       Date:  2016-09-29       Impact factor: 8.860

Review 9.  [Restless legs syndrome, periodic limb movements, and psychopharmacology].

Authors:  S Cohrs; A Rodenbeck; M Hornyak; D Kunz
Journal:  Nervenarzt       Date:  2008-11       Impact factor: 1.214

10.  Gabapentin enacarbil - clinical efficacy in restless legs syndrome.

Authors:  Pinky Agarwal; Alida Griffith; Henry R Costantino; Narendra Vaish
Journal:  Neuropsychiatr Dis Treat       Date:  2010-05-06       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.